Androgen receptor antagonist Treatment of metastatic castration-resistant prostate cancer Treatment of metastatic breast cancer

Treatment of prostate cancer cells with the nonsteroidal an-tiandrogen enzalutamide has improved patients' survival and quality of life. Since prostate cancers may progress after enzalutamide treatment, there is a need to test new antian-drogenic compounds such as darolutamide and pruxelu-tamide. Pruxelutamide (formerly proxalutamide, GT-0918) was developed on the core structure of enzalutamide. Metabolom-ic profiling of prostate cancer cells treated with pruxelutamide was performed. Metabolism of glutamate, glutathione and pyrimidine were affected by pruxelutamide. Those metabol- ic effects of pruxelutamide were not observed in androgen receptor-negative prostate cells. In vitro pruxelutamide effects of proliferation and migration were investigated and it was found that its effect is stronger compared to that of enzalu-tamide. A clinical phase I study with pruxelutamide has been carried out. In addition, therapeutic potential of pruxelutamide was confirmed in breast cancer which is in part regulated by the androgen receptor. More clinical studies with pruxelu-tamide need to be performed in order to determine its role in prostate cancer treatment in combination with other agents.